Csl Ltd (QX) (CSLLY) Actualités

Form 3 - Initial statement of beneficial ownership of securities

Securities Registration (ads, Immediate) (f-6ef)

    As filed with the Securities and Exchange Commission on June 17, 2022 Registration No. 333-_____...

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient Awards Program Supports Novel Research of Immunoglobulin Therapy for...

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 PR Newswire TORONTO...

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A PR Newswire TORONTO, June 24...

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers Panel of experts examines how...

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress PR Newswire KING OF PRUSSIA, Pa., June 16, 2015 More...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1...

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award CSL Behring Recognized for its Longstanding Commitment to...

Science, Information, And Technology Driving Evolution Of Global Healthcare

Science, Information, And Technology Driving Evolution Of Global Healthcare Industry serves critical role in advancing healthcare and improving...

CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science

CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science PR Newswire MARBURG, Germany, April 23, 2015 CSL Behring...

CSL Behring Marks World Hemophilia Day by Renewing Pledge to World Federation of Hemophilia

CSL Behring Marks World Hemophilia Day by Renewing Pledge to World Federation of Hemophilia PR Newswire MONTREAL and KING OF PRUSSIA, Pa., April...

European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients

European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients PR Newswire KING OF...

The Lancet Publishes CSL Behring's Kcentra® Phase III Data

The Lancet Publishes CSL Behring's Kcentra® Phase III Data Study Finds Kcentra® is Superior to Plasma in Patients Needing Warfarin Reversal for...

CSL Behring to Provide $80,000 in Scholarship Funding For Low-Income Students in Philadelphia Area

CSL Behring to Provide $80,000 in Scholarship Funding For Low-Income Students in Philadelphia Area Company and Employees Cultivate a Culture of...